8 stock analysts forecast that the average 12-month stock price forecast for PLNHF stock represents an increase of 93.7% from its March 15th close. and, on average, these analysts rate PLNHF stock as a BUY.
Read More »Aurora Cannabis: Analysts Forecast Only An 80% Upside
Given that Aurora's stock price has fallen below Nasdaq's minimum listing requirement of $1.00/share, it could be forced to institute a second reverse stock split.
Read More »Seelos: 10 Analysts Forecast A 912% Increase In Its Stock By End Of 2023
The progress Seelos Therapeutics, Inc. (Nasdaq: SEEL) is achieving in its multi-faceted clinical trials has investors taking a long hard look at what Seelos is all about. This article does just that, looking at what the company is focused on, its clinical trial progress to date, its latest quarterly financials, its management and the investment risks associated with it.
Read More »MindMed: Wall Street Analysts Forecast A 1110% Increase In 2023
Based on 3 Wall Street analysts offering 12 month price targets for Mind Medicine in the last 3 months, the average price target is $40.37 with a high forecast of $75.06 and a low forecast of $21.02. The average price target represents a +1108.7% increase.
Read More »Ascend Wellness: Analysts Forecast 50% – 242% Upside Within Year
Wall Street analysts have an average price target representing a 146% change from today's (March 14th) closing price.
Read More »Organigram: 15 Analysts Forecast 131% Upside WithIn Year
Management optimism and consensus forecast by 15 Wall Street analysts of a 131% increase in the Company's stock price suggests things are looking up for Organigram in Fiscal 2023.
Read More »Compass Pathways: 8 Wall Street Analysts Forecast A +400% Increase
Based on 8 Wall Street analysts the average price target for Compass is $42.75 with a high forecast of $120.00 and a low forecast of $19.00. The average price target represents a +403.5% change from its closing price of $8.49 on March 3rd, 2023.
Read More »Cybin Inc.: 6 Analysts Forecast An Average Return Of 1165% In 2023
A review of Cybin Inc.'s latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock over the next 12 months.
Read More »Atai Life Sciences: Wall Street Analysts Forecast An 800% Increase
A review of Atai Life Sciences' latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock over the next 12 months.
Read More »Zynerba:+2,000% (Yes, 2,000%!) Increase In Stock Forecast In 2023 – Here’s Why
From my analysis of Zynerba Pharmaceuticals Inc. (ZYNE) and the extremely optimistic analyst stock price projections stated above, I think Zynerba would make a great buy and hold investment.
Read More »